Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Anti-angiogenic therapy in glioma.

Butowski N.

Clin Transl Oncol. 2011 May;13(5):294-300. doi: 10.1007/s12094-011-0657-2. Review.

PMID:
21596656
2.

Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.

Miletic H, Niclou SP, Johansson M, Bjerkvig R.

Expert Opin Ther Targets. 2009 Apr;13(4):455-68. doi: 10.1517/14728220902806444 . Review.

PMID:
19335067
3.

The emerging role of anti-angiogenic therapy for malignant glioma.

Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ.

Curr Treat Options Oncol. 2008 Feb;9(1):1-22. doi: 10.1007/s11864-008-0052-6. Epub 2008 Feb 7. Review.

PMID:
18256938
4.

Evolving strategies: future treatment of glioblastoma.

Chamberlain M.

Expert Rev Neurother. 2011 Apr;11(4):519-32. doi: 10.1586/ern.11.30. Review.

PMID:
21469925
5.

Angiogenesis in malignant glioma--a target for antitumor therapy?

Tuettenberg J, Friedel C, Vajkoczy P.

Crit Rev Oncol Hematol. 2006 Sep;59(3):181-93. Epub 2006 Jul 24. Review.

PMID:
16860996
6.

Novel anti-angiogenic therapies for malignant gliomas.

Norden AD, Drappatz J, Wen PY.

Lancet Neurol. 2008 Dec;7(12):1152-60. doi: 10.1016/S1474-4422(08)70260-6. Review.

PMID:
19007739
7.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
8.

[Anti-angiogenic strategies in glioblastoma].

Guillamo JS.

Rev Neurol (Paris). 2011 Oct;167(10):662-7. doi: 10.1016/j.neurol.2011.07.008. Epub 2011 Sep 1. Review. French.

PMID:
21889779
9.

Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.

Argyriou AA, Giannopoulou E, Kalofonos HP.

Oncology. 2009;77(1):1-11. doi: 10.1159/000218165. Epub 2009 May 12. Review.

PMID:
19439998
10.

New treatment strategies for malignant gliomas.

Sathornsumetee S, Rich JN.

Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104. Review.

PMID:
16831080
11.

Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas.

Wong ML, Prawira A, Kaye AH, Hovens CM.

J Clin Neurosci. 2009 Sep;16(9):1119-30. doi: 10.1016/j.jocn.2009.02.009. Epub 2009 Jun 24. Review.

PMID:
19556134
12.

Therapeutic anti-angiogenesis for malignant brain tumors.

Kirsch M, Santarius T, Black PM, Schackert G.

Onkologie. 2001 Oct;24(5):423-30. Review.

PMID:
11694768
13.

Anti-angiogenic approaches to malignant gliomas.

Soffietti R, Trevisan E, Bertero L, Bosa C, Ruda R.

Curr Cancer Drug Targets. 2012 Mar;12(3):279-88. Review.

14.

Angiogenic inhibition in high-grade gliomas: past, present and future.

Jo J, Schiff D, Purow B.

Expert Rev Neurother. 2012 Jun;12(6):733-47. doi: 10.1586/ern.12.53. Review.

PMID:
22650175
15.

Progress report on the potential of angiogenesis inhibitors for neuro-oncology.

Purow B, Fine HA.

Cancer Invest. 2004;22(4):577-87. Review.

PMID:
15565816
16.

Cilengitide treatment for malignant glioma: current status and future direction.

Kurozumi K, Ichikawa T, Onishi M, Fujii K, Date I.

Neurol Med Chir (Tokyo). 2012;52(8):539-47. Review.

17.

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Verhoeff JJ, van Tellingen O, Claes A, Stalpers LJ, van Linde ME, Richel DJ, Leenders WP, van Furth WR.

BMC Cancer. 2009 Dec 16;9:444. doi: 10.1186/1471-2407-9-444. Review.

18.

Antiangiogenic agents for the treatment of glioblastoma.

Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT.

Expert Opin Investig Drugs. 2007 Dec;16(12):1895-908. Review.

PMID:
18041999
19.

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.

Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ.

Expert Opin Biol Ther. 2008 Apr;8(4):541-53. doi: 10.1517/14712598.8.4.541 . Review.

20.

Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.

Shibuya M.

FEBS J. 2009 Sep;276(17):4636-43. doi: 10.1111/j.1742-4658.2009.07175.x. Epub 2009 Jul 31. Review.

Supplemental Content

Support Center